Sumitomo Pharma

4506 · TSE · JPY

¥1,613.50Change from previous close: −1.31%Absolute change: −¥21.50

Close · October 2, 2026

Company profile

Sumitomo Pharma Co., Ltd. Manufactures, purchases, and sells pharmaceutical products for medical treatment in Japan, North America, and Asia. It offers therapeutic agents for parkinson's disease, type 2 diabetes, uterine fibroids and endometriosis, overactive bladder, and pediatric congenital athymia. The company also provides atypical antipsychotic, generic products, antiepileptic, atypical antipsychotic, and carbapenem antibiotic. In addition, it offers veterinary medicines, medical devices, etc. The company has collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was formerly known as Sumitomo Dainippon Pharma Co., Ltd. and changed its name to Sumitomo Pharma Co., Ltd. in April 2022. The company was incorporated in 1897 and is headquartered in Osaka, Japan. Sumitomo Pharma Co., Ltd. is a subsidiary of Sumitomo Chemical Company, Limited.

Company facts

Industry
Drug Manufacturers - Specialty & Generic
Country
Japan
Headquarters
2-6-8 Doshomachi, 541-0045, Osaka
Listing
4506 · TSE
Indices
Nikkei 225
Currency
JPY
ISIN
JP3495000006